A Look At Our Future: A Letter from AZBio’s CEO

AZ Bio Logo

 

 

Dear Members of Arizona’s Bioscience and Business Community,

Our industry is making progress every day to develop new  technologies and services that will support and sustain life, feed the world, and fuel it.  What we do matters.  More importantly, the next generation of bioscience leaders will give life to new innovations, some we can only yet imagine.

As graduations commence across our state, it is my honor to share with you the list of 21 students from Arizona’s High Schools and Universities who have been selected to represent our industry’s future and present their work at the AZBio Expo on May 30th in the Student Discovery Zone sponsored by Northern Arizona University.   To see the list of students and their projects, please click here.

I hope you will be attending the AZBio Expo on May 30th and will have the opportunity to visit the students in the Student Discovery Zone and to learn about their work and  to encourage them in their efforts.  (Some of these future leaders are now graduating and are ready to join your companies.  It is so important that we keep Arizona talent right here in Arizona.)

One last request.  If you , like so many of us, will be attending commencements across the state this May to congratulate graduates from Kindergarten through Doctorate Programs, please take a moment to seek out a teacher and thank them for what they do.  Together, we are building Arizona’s bioscience industry.  Through their efforts, they are shaping our future.

Have a great weekend and to all of our graduates, and the family members who helped them along their journey, CONGRATULATIONS!

Joan Koerber-Walker
President and CEO
Arizona BioIndustry Association

____________________________________________________
Learn more about Arizona’s bioindustry on May 30thwww.AZBioExpo.com
www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO YouTube:  www.youtube.com/azbio1

2013 EY Beyond Borders Report for the Life Science Industry

The business climate for the biotechnology industry remains challenging. In today’s “new normal,” venture capitalists are more selective, IPOs more elusive and alliance partners more demanding. And even as biotech companies grapple with these challenges, health care systems are undergoing a fundamental shift toward outcomes and pay-for-performance.

How is the industry dealing with the twin challenges of boosting operating efficiency and demonstrating economic value?

Are “HOLNets” gaining traction and making R&D more efficient?

What are companies doing differently to collect data and demonstrate the economic value of their products?

Ernst & Young’s Beyond Borders offers insights on these questions and more.

Want to learn more? 

Contact Phil Howard and the E&Y Life Sciences Team

in Phoenix at (602) 322-3000.